JPX · 4579.T
RaQualia Pharma Inc.
¥638-¥9 (-1.39%)
RaQualia Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.45% below the high.
Loading market information…
JPX · 4888.T · JPY
Stock price, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Stella Pharma Corporation’s quoted price sits in the lower half of its reported 52-week range, 58.69% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Stella Pharma Corporation’s next earnings report is currently expected on Nov 13, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Stella Pharma Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Stella Pharma Corporation is a pharmaceutical company that handles the complete process of drug development, from research and manufacturing to distribution. A core area of its specialization is in therapeutic agents for boron neutron capture therapy (BNCT). Their product lineup includes SPM-011, a boron-containing drug designed for BNCT, which is utilized in the treatment of head and neck cancer, recurrent malignant glioma, meningioma, malignant melanoma, and angiosarcoma. Founded in 2007, Stella Pharma Corporation maintains its headquarters in Osaka, Japan.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:18 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥638-¥9 (-1.39%)
RaQualia Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.45% below the high.
$1.39-$0.01 (-0.71%)
MediciNova, Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.36% below the high.
¥485-¥8 (-1.62%)
Advantage Risk Management Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 30.01% below the high.
¥149-¥5 (-3.25%)
Kidswell Bio Corporation’s quoted price sits in the lower half of its reported 52-week range, 53.44% below the high.
¥89-¥3 (-3.26%)
Chiome Bioscience Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.56% below the high.
¥79-¥1 (-1.25%)
Nano Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.49% below the high.
¥701-¥6 (-0.85%)
StemCell Institute Inc.’s quoted price sits in the lower half of its reported 52-week range, 28.18% below the high.
¥1,884+¥9 (+0.48%)
AS Partners Co. Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.48% below the high.
